Moreover, several randomized controlled trials concerning the epidermal growth factor receptor (EGFR) inhibitors (erlotinib, cetuximab, lapatinib, or panitumumab) did not achieve effective outcomes in advanced CCA (57–60, 156) (Table 2). The gene discussed is EGFR; the disease is cholangiocarcinoma.